Urinary angiotensinogen as a biomarker of chronic kidney disease: Ready for prime time?

Nephrology Dialysis Transplantation

Volumn 27, Issue 8, 2012, Pages 3010-3013

  Burns, Kevin D ^a   Hiremath, Swapnil ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

angiotensinogen; biomarker; urine

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; BIOLOGICAL MARKER;

ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN URINE LEVEL; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION;

ANGIOTENSINOGEN; FEMALE; HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84864578528     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs166     Document Type: Article

References (24)

1. National Research Council. Evaluation of biomarkers and surrogate endpoints in chronic disease. The National Academies Press, Washington, D.C.: 2010; 1-336.
2. Mills KT, Kobori H, Hamm LL et al. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transplant (this issue).
3. Kobori H, Nangaku M, Navar LG et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287.
4. Kobori H, Nishiyama A, Abe Y et al. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 2003; 41: 592-597.
5. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486.
6. Sachetelli S, Liu Q, Zhang SL et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int 2006; 69: 1016-1023.
7. Liu F, Brezniceanu ML, Wei CC et al. Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol 2008; 19: 269-280.
8. Liu F, Wei CC, Wu SJ et al. Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int 2009; 75: 156-166.
9. Lo CS, Liu F, Shi Y et al. Dual RAS blockade normalizes angiotensin- converting enzyme-2 expression, prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol 2012; 302: F840-F852.
10. Navar LG, Prieto MC, Satou R et al. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol 2011; 11: 180-186.
11. Kobori H, Prieto-Carrasquero MC, Ozawa Y et al. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 2004; 43: 1126-1132.
12. Katsurada A, Hagiwara Y, Miyashita K et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007; 293: F956-F960.
13. Kobori H, Alper AB, Jr, Shenava R et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009; 53: 344-350.
14. Kobori H, Ohashi N, Katsurada A et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008; 2: 349-354.
15. Aybal Kutlugun A, Altun B, Buyukasik Y et al. Elevated urinary angiotensinogen a marker of intrarenal renin angiotensin system in hypertensive renal transplant recipients: does it play a role in development of proteinuria in hypertensive renal transplant patients? Transpl Int 2012; 25: 13-18.
16. Urushihara M, Kondo S, Kagami S et al. Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity. Am J Nephrol 2010; 31: 318-325.
17. Yamamoto T, Nakagawa T, Suzuki H et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007; 18: 1558-1565.
18. Nishiyama A, Konishi Y, Ohashi N et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant 2011; 26: 170-177.
19. Jang HR, Kim SM, Lee YJ et al. The origin and the clinical significance of urinary angiotensinogen in proteinuric IgA nephropathy patients. Ann Med 2011; epub ahead of print doi:10.3109/07853890. 2011.558518.
20. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
21. Susic D, Frohlich ED, Kobori H et al. Salt-induced renal injury in SHRs is mediated by AT1 receptor activation. J Hypertens 2011; 29: 716-723.
22. Lara LS, McCormack M, Semprum-Prieto LC et al. AT1 receptormediated augmentation of angiotensinogen, oxidative stress, and inflammation in ANG II-salt hypertension. Am J Physiol Renal Physiol 2012; 302: F85-F94.
23. Konishi Y, Nishiyama A, Morikawa T et al. Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy. Hypertension 2011; 58: 205-211.
24. Vegter S, Perna A, Postma MJ et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23: 165-173